Myocardial Infarction Market

Market Overview:

The 7 major myocardial infarction markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.94% during 2024-2034.

The myocardial infarction market has been comprehensively analyzed in IMARC's new report titled "Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myocardial infarction, also known as a heart attack, is a life-threatening condition that develops when blood flow to the heart muscle is blocked, leading to tissue damage. The most prominent symptom is severe and persistent chest pain or discomfort that may spread to the arms, neck, jaw, or back. This pain is often accompanied by shortness of breath, sweating, nausea, lightheadedness, and an overwhelming sense of anxiety. Some patients may also experience unusual fatigue, heart palpitations, a feeling of indigestion, etc. The diagnosis of myocardial infarction involves a combination of medical history evaluation, physical examination, and diagnostic tests. The healthcare provider will inquire about the patient's symptoms, risk factors, and medical history. During the physical exam, they may monitor heart and lung conditions, check blood pressure, and assess overall signs of distress. Various diagnostic procedures, such as an electrocardiogram (ECG), blood tests, imaging techniques like echocardiography or coronary angiography, etc., are also performed to confirm the diagnosis. These tests help to identify abnormal changes in the heart's electrical activity, detect the presence of certain enzymes released during a heart attack, and visualize the blood flow to the heart.

The increasing cases of coronary artery diseases in which plaque builds up on the inner walls of the arteries and reduces blood flow to the heart muscle are primarily driving the myocardial infarction market. Furthermore, the rising prevalence of various associated risk factors, including high cholesterol levels, excessive alcohol consumption, smoking, lack of physical activity, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of beta-blockers, such as metoprolol, bisoprolol, carvedilol, etc., since they decrease the workload on the heart by slowing the heart rate and lowering blood pressure, thereby promoting healing and reducing the likelihood of future heart attacks, is also creating a positive outlook for the market. Moreover, the increasing utilization of radial access surgery on account of its several associated benefits, including a lower risk of access-site complications, better patient comfort, early mobilization, etc., is further augmenting the market growth. Apart from this, the escalating demand for drug-eluting stents, which have drastically reduced the incidence of restenosis and enhanced the effectiveness of stent placement, is expected to drive the myocardial infarction market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the myocardial infarction market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for myocardial infarction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myocardial infarction market in any manner.

Recent Developments:

• In May 2024, BioCardia released primary endpoint results from the CardiAMP cell therapy in chronic myocardial ischemia trial's open-label roll-in cohort. The open-label roll-in cohort of patients with chronic myocardial ischemia and refractory angina showed an average increase in exercise tolerance of 107 seconds and an 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment. All the patients reacted effectively to therapy, as evidenced by increased (better) exercise tolerance and a significant reduction in angina.

Key Highlights:

• The most prevalent type of coronary heart disease is myocardial infarction.
• Every year, around one million people in the United States suffer a myocardial infarction.
• About 30% of people suffering from this condition have atypical symptoms. Women are more likely to present with arm pain, neck discomfort, or fatigue than with chest pain.
• Approximately 5% of people over the age of 75 have experienced a myocardial infarction with no prior symptoms.
• It accounts for more than 15% of deaths each year, with the great majority of patients suffering from non-ST-segment elevation myocardial infarction (NSTEMI) rather than ST-segment elevation myocardial infarction (STEMI).
• STEMIs occur twice as frequently in men as in women.

Drugs:

Lovenox refers to a low molecular weight heparin used to treat STEMI managed either medically or with subsequent percutaneous coronary intervention. The recommended Lovenox dose is a single IV bolus of 30 mg plus a 1 mg/kg SC dose, followed by 1 mg/kg delivered SC every 12 hours.

Tenecteplase biosimilar (GNR-060) is under development by Generium for the treatment of myocardial infarction. The drug is administered through an intravenous bolus route.

Dutogliptin tartrate (REC-01) is under development for the treatment of acute and post-myocardial infarction. The therapeutic candidate is made as a solution and delivered via subcutaneous injection. The medication candidate is a DPP-IV inhibitor that is also used in conjunction with G-CSF.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the myocardial infarction market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the myocardial infarction market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current myocardial infarction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the myocardial infarction market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the myocardial infarction market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the myocardial infarction market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of myocardial infarction across the seven major markets?
• What is the number of prevalent cases (2018-2034) of myocardial infarction by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of myocardial infarction by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of myocardial infarction by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with myocardial infarction across the seven major markets?
• What is the size of the myocardial infarction patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of myocardial infarction?
• What will be the growth rate of patients across the seven major markets?
   

Myocardial Infarction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for myocardial infarction drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myocardial infarction market?
• What are the key regulatory events related to the myocardial infarction market?
• What is the structure of clinical trial landscape by status related to the myocardial infarction market?
• What is the structure of clinical trial landscape by phase related to the myocardial infarction market?
• What is the structure of clinical trial landscape by route of administration related to the myocardial infarction market?